The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Exploring current and investigational GPRC5D-targeted therapies in multiple myeloma
In this exclusive virtual session, Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, is joined by Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, and Susan Bal, MD, University of Alabama at Birmingham, Birmingham, AL, to discuss the evolving landscape of GPRC5D-targeted therapies in multiple myeloma, from the clinical experience with talquetamab to emerging investigational approaches. The experts review clinical data on GPRC5D-directed CAR T-cell therapies, dual-targeted strategies, trispecific antibodies, and antibody-drug conjugates, highlighting efficacy, safety, and potential approaches to overcome resistance. They also consider the remaining evidence gaps and how these novel therapies may influence treatment sequencing, earlier-line treatment strategies, and the future of multiple myeloma management. This discussion took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
